Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th
September 23 2021 - 9:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a
clinical-stage global developer of cell-based technologies and
therapeutics, today announced that it will be presenting at
the Benzinga Healthcare Small Cap Conference, which is being held
virtually from September 29 – 30, 2021.
David Jin, M.D., Ph.D., President and Chief
Executive Officer, and Luisa Ingargiola, Chief Financial Officer of
Avalon GloboCare will present on Thursday, September 30th at 10:50
AM Eastern Time. Management will also participate in one-on-one
meetings with investors throughout the conference.
Investors can register for the conference here:
https://www.benzinga.com/events/small-cap/healthcare/.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a
clinical-stage, vertically integrated, leading CellTech
bio-developer dedicated to advancing and empowering innovative,
transformative immune effector cell therapy, exosome technology, as
well as COVID-19 related diagnostics and therapeutics. Avalon also
provides strategic advisory and outsourcing services to facilitate
and enhance its clients' growth and development, as well as
competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of
verticals from innovative R&D to automated bioproduction and
accelerated clinical development, Avalon is establishing a leading
role in the fields of cellular immunotherapy (including CAR-T/NK),
exosome technology (ACTEX™), and regenerative therapeutics. For
more information about Avalon GloboCare, please visit
www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's
developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release
may constitute "forward-looking statements." Forward-looking
statements provide current expectations of future events based on
certain assumptions and include any statement that does not
directly relate to any historical or current fact. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors as disclosed in
our filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon
GloboCare Corp.4400 Route 9, Suite 3100Freehold, NJ
07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo
Communications, LLCTel: (212) 671-1020 Ext.
304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2024 to May 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From May 2023 to May 2024